TCM
ACTU

Tang Capital Management’s Actuate Therapeutics ACTU Stock Holding History

Tang Capital Management’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,243
Closed -$32K – 209
2025
Q2 		$32K Buy
+5,243
New +$45.8K ﹤0.01% 199

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
SWA
SFMG Wealth Advisors Plano, Texas $1.48B AUM 15.85% 1-Year Est. Return

Tang Capital Management's ACTU Position: Q3 2025 in Review

Tang Capital Management sold out of Actuate Therapeutics (ACTU) in Q3 2025, closing a stake of 5,243 shares — an estimated $32K sold.

Tang Capital Management first reported a position in ACTU in Q2 2025 and held it in 1 quarter. The position peaked at $32K in Q2 2025. 43 funds tracked by Wall St. Rank hold ACTU as of Q3 2025.

  • Tang Capital Management reported no remaining Actuate Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Tang Capital Management sold 5,243 Actuate Therapeutics shares in Q3 2025, an estimated $32K.
  • Tang Capital Management first reported a position in Actuate Therapeutics in Q2 2025 and held it in 1 quarter.
  • Tang Capital Management's Actuate Therapeutics position peaked at $32K in Q2 2025.
  • 43 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q3 2025.

Based on Tang Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.